Back to Results
First PageMeta Content
Pharmacology / Protease inhibitors / Amides / Organofluorides / Antiretroviral drug / Integrase inhibitors / Lopinavir/ritonavir / Tenofovir/emtricitabine / Lopinavir / Chemistry / Organic chemistry / Fixed dose combination


Lopinavir/ritonavir M10-336 Clinical Study Report 2.0 Synopsis
Add to Reading List

Document Date: 2014-12-18 17:16:43

Open Document

File Size: 73,70 KB

Share Result on Facebook

Company

AEs / Abbott Laboratories / ITT / /

Country

Poland / Puerto Rico / France / United States / Italy / Canada / Spain / /

Event

FDA Phase / /

IndustryTerm

treatment / dual-energy x-ray absorptiometry / food / /

MedicalCondition

abdominal pain / lipodystrophy / viral encephalitis / renal and urinary disorders AEs / headache / herpes zoster / nasopharyngitis / Bronchitis / nausea / Serious infections / diabetes / HIV RNA / viremia / vomiting / Klebsiella infection / renal and urinary disorders / non-infectious hepatitis / onset diabetes mellitus AEs / soluble serum tumor necrosis / renal failure / acute pancreatitis / depression / Gastrointestinal disorders / birth defects / sepsis / upper respiratory tract infection / /

Organization

FDA / Federal Trade Commission / /

Position

investigator / Infected Subjects Coordinating Investigator / /

Product

Tenofovir Disoproxil Fumarate / M10-336 / /

Technology

pharmacokinetics / x-ray / FDA TLOVR algorithm / /

SocialTag